Clinical Trial Update: Extended Long-Term Safety Study of KW-6500 [Phase 3]

View source ↗

Summary

This document provides an update on the extended long-term safety study of KW-6500 in Parkinson's disease, a Phase 3 trial that has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• KW-6500

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED